Pharma Mar S.A (PHM) | Stock Overview & Key Data

Frequently Asked Questions

What is PHM's 52-week high and low?

In the last 52 weeks, Pharma Mar S.A reached a high of €105.80 (on March 3, 2025) and a low of €31.82 (on June 28, 2024).

What is the market cap and P/E ratio for PHM?

Curious about Pharma Mar S.A's size and valuation? Its market capitalization stands at 1.43B. When it comes to valuation, the P/E ratio (trailing twelve months) is 73.23, and the forward P/E (looking ahead) is 22.43.

Does PHM pay dividends? If so, what's the yield?

Yes, Pharma Mar S.A is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.79%, and the company is expected to pay out €2.60 per share over the coming year.

Who are Pharma Mar S.A's main competitors or similar companies to consider before investing?

When looking at Pharma Mar S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Metrovacesa S.A MVC	1.59B	Consumer Cyclical	Residential Construction	29.29%	56.07%
Neinor Homes, S.A HOME	1.02B	Consumer Cyclical	Residential Construction	14.65%	19.47%
Mapfre S.A MAP	10.15B	Consumer Cyclical	Resorts & Casinos	54.93%	96.43%
Grupo Catalana GCO	5.78B	Consumer Cyclical	Apparel Retail	30.67%	73.45%
Unicaja Banco S.A UNI	4.86B	Consumer Cyclical	Apparel Manufacturing	52.42%	110.00%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Pharma Mar S.A.? (e.g., ROE, Debt/Equity)

To get a sense of Pharma Mar S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.19%, the Debt to Equity ratio from the most recent quarter is 26.30, and its Gross Profit Margin stands at 91.25%.

What is the recent revenue and earnings growth for PHM?

Looking at Pharma Mar S.A's growth, its revenue over the trailing twelve months (TTM) was €176M. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.30%, and quarterly earnings saw a YoY growth of 2.35%.

How much of PHM stock is held by insiders and institutions?

Wondering who owns Pharma Mar S.A stock? Company insiders (like executives and directors) hold about 29.37% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 8.62%.

For more common questions about our data, please visit our About Data page.